A Novel FLCN Variant in a Suspected Birt-Hogg-Dubè Syndrome Patient

Int J Mol Sci. 2023 Aug 4;24(15):12418. doi: 10.3390/ijms241512418.

Abstract

Subjects with pathogenic (PV) and likely pathogenic (LPV) FLCN variants have an increased risk of manifesting benign and malignant disorders that are related to Birt-Hogg-Dubé syndrome (BHDS): an autosomal dominantly inherited disorder whose severity can vary significantly. Renal cell carcinoma (RCC) development in BHD (Birt-Hogg-Dubé) patients has a very high incidence; thus, identifying this rare syndrome at early stages and preventing metastatic spread is crucial. Over the last decade, the advancement of Next Generation Sequencing (NGS) and the implementation of multigene panels for hereditary cancer syndromes (HCS) have led to a subsequent focus on additional genes and variants, including those of uncertain significance (VUS). Here, we describe a novel FLCN variant observed in a subject manifesting disorders that were suspected to be related to BHDS and with a family history of multiple cancers.

Keywords: FLCN; NGS; case report; genetic testing; genetic variants.

Publication types

  • Case Reports

MeSH terms

  • Birt-Hogg-Dube Syndrome* / genetics
  • Birt-Hogg-Dube Syndrome* / pathology
  • Carcinoma, Renal Cell* / genetics
  • Humans
  • Kidney Neoplasms* / genetics
  • Kidney Neoplasms* / pathology
  • Neoplastic Syndromes, Hereditary*
  • Proto-Oncogene Proteins / genetics
  • Tumor Suppressor Proteins / genetics

Substances

  • FLCN protein, human
  • Proto-Oncogene Proteins
  • Tumor Suppressor Proteins

Grants and funding

This research received no external funding.